Argenica Therapeutics Ltd (AU:AGN) has released an update.
Argenica Therapeutics Ltd reports significant advances in its Phase 2 clinical trial, with 23 of 92 patients already dosed and positive feedback from trial sites, while also announcing a successful $12 million fundraising to ensure trial completion. Additionally, the company’s pre-clinical study on ARG-007 has shown promising results in reducing brain cell damage in a traumatic brain injury model. Argenica, with a robust cash reserve of $15.9 million, is set to continue its clinical and pre-clinical studies into neurological conditions, backed by substantial non-dilutive funding support.
For further insights into AU:AGN stock, check out TipRanks’ Stock Analysis page.
